{
  "source": "PA-Notification-Alunbrig.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1219-9\nProgram Prior Authorization/Notification\nMedication Alunbrig® (brigatinib)\nP&T Approval Date 6/2017, 6/2018, 6/2019, 6/2020, 6/2021, 9/2021, 9/2022, 9/2023,\n9/2024\nEffective Date 11/17/2024\n1. Background:\nAlunbrig (brigatinib) is a kinase inhibitor indicated for the treatment of adult patients with\nanaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).\nThe National Cancer Comprehensive Network (NCCN) also recommends Alunbrig as first-line\ntherapy for ALK-positive recurrent, advanced, or metastatic NSCLC, for the treatment of\ninflammatory myofibroblastic tumor (IMT) with ALK translocation, ALK-positive metastatic\nbrain cancer from NSCLC, and as first-line or subsequent therapy for anaplastic lymphoma\nkinase (ALK)-fusion targeted relapsed/refractory, symptomatic Erdheim-Chester Disease\n(ECD). The NCCN also recommends Alunbrig for ALK-positive relapsed or refractory\nanaplastic large cell lymphoma as palliative intent therapy or second-line and subsequent\ntherapy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Alunbrig will be approved based on the following criterion:\na. Member is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Non-Small Cell Lung Cancer (NSCLC)\n1. Initial Authorization\na. Alunbrig will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n© 2024 UnitedHealthcare Service",
    "ll Lung Cancer (NSCLC)\n1. Initial Authorization\na. Alunbrig will be approved based on all of the following criteria:\n(1) Diagnosis of non-small cell lung cancer (NSCLC)\n© 2024 UnitedHealthcare Services Inc.\n1\n-AND-\n(2) Disease is one of the following:\n(a) Metastatic\n(b) Recurrent\n(c) Advanced\n-AND-\n(3) Tumor is anaplastic lymphoma kinase (ALK)-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alunbrig will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alunbrig\ntherapy\nAuthorization will be issued for 12 months.\nC. Soft Tissue Sarcoma / Uterine Neoplasms\n1. Initial Authorization\na. Alunbrig will be approved based on both of the following criteria:\n(1) Diagnosis of inflammatory myofibroblastic tumor (IMT)\n-AND-\n(2) Presence of ALK translocation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alunbrig will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alunbrig\ntherapy\nAuthorization will be issued for 12 months.\nD. Histiocytic Neoplasms\n1. Initial Authorization\n© 2024 UnitedHealthcare Services Inc.\n2\na. Alunbrig will be approved based on all of the following criteria:\n(1) Diagnosis of symptomatic Erdheim-Chester Disease\n-AND-\n(2) Used as targeted therapy ALK-fusion\n-AND-\n(3) Disease is one of the following:\n(a) Relapsed\n(b) Refractory\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alunbrig will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alunbrig\ntherapy.\nAuthorization will be issued for 12 months.\nE. Central Nervous System (CNS) Cancers\n1. Initial Authorization\na. Alunbrig will be approved based on both of the following criteria:\n(1) Diagnosis of metastatic brain cancer from NSCLC\n-AND-\n(2) Tumor is anaplastic lymphoma kinase (ALK)-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alu",
    "llowing criteria:\n(1) Diagnosis of metastatic brain cancer from NSCLC\n-AND-\n(2) Tumor is anaplastic lymphoma kinase (ALK)-positive\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alunbrig will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alunbrig\ntherapy\nAuthorization will be issued for 12 months.\nF. Anaplastic Large Cell Lymphoma\n© 2024 UnitedHealthcare Services Inc.\n3\n1. Initial Authorization\na. Alunbrig will be approved based on all of the following criteria:\n(1) Diagnosis of anaplastic large cell lymphoma\n-AND-\n(2) Tumor is anaplastic lymphoma kinase (ALK)-positive\n-AND-\n(3) Disease is relapsed or refractory\n-AND-\n(4) Used as palliative intent therapy or second-line and subsequent therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Alunbrig will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Alunbrig\ntherapy\nAuthorization will be issued for 12 months.\nG. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services Inc.\n4\n4. References:\n1. Alunbrig [package insert]. Lexington, MA: Ariad Pharmaceutica",
    "ses varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services Inc.\n4\n4. References:\n1. Alunbrig [package insert]. Lexington, MA: Ariad Pharmaceuticals, Inc; February 2022.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nwww.nccn.org. Accessed August 8, 2024.\nProgram Prior Authorization/Notification - Alunbrig (brigatinib)\nChange Control\n6/2017 New program.\n6/2018 Updated background and criteria to include off label NCCN\nrecommendations. Updated reference.\n6/2019 Updated background and criteria to include NCCN recommendation for\nfirst-line therapy for ALK-positive NSCLC. Updated references.\n6/2020 Annual review. Added general NCCN recommendations for use\ncriteria. Updated references.\n6/2021 Annual review. Added advanced disease to NSCLC criteria. Added\ncriteria for soft tissue sarcoma per NCCN. Updated background and\nreferences.\n9/2021 Corrected error listing Alunbrig instead of Alunbrig in reauthorization\ncriteria.\n9/2022 Annual review. Added criteria per NCCN recommendations for\nhistiocytic neoplasms. Added state mandate and updated background\nand references.\n9/2023 Annual review. Updated histiocytic neoplasm formatting with no\nchange to clinical criteria. Added criteria for CNS cancer, IMT tumors,\nand uterine neoplasms per NCCN guidelines.\n9/2024 Annual review. Updated background and coverage criteria for\nanaplastic large cell lymphoma per NCCN. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n5"
  ]
}